Cardiology biotech Kardigan filed for a Nasdaq IPO under ticker {$KARD}, joining a growing roster of clinical-stage drug developers tapping reopened capital markets.
May 26, 2026 08:15 PM EDT
IPOs
Kardigan readies Nasdaq IPO to back three cardio drugs
Kyle LaHucik
Biotech Correspondent
Cardiology biotech Kardigan prices its Nasdaq IPO at $16, the top of range, raising $400M ahead of a Thursday debut.
Kardigan launches $320M IPO to fund three late-stage cardio drugs as biotech listings hit a post-pandemic high.
Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies down the clinical…
Founded by former MyoKardia executives, the startup has in mid- to late-stage testing three medicines licensed from the likes of…
Including the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the most…
Kardigan raised $400 million in its upsized Nasdaq IPO, pricing at $16 per share at the top of its range, signaling renewed…
